News Articles​​

• Stop TB head: TB still the ‘Cinderella’ in Global Fund disease split
  
• Assessing Blame for Deaths of Indian Boarding School Students
  
• Mice infected with Mycobacterium tuberculosis are resistant to secondary infection with SARS-CoV-2
  
• Five developments in paediatric tuberculosis
  
• How COVID-19 threatens to undo years of progress in TB control
  
• WILL THE CHANGE IN THE GLOBAL FUND DISEASE SPLIT REDUCE TB DEATHS?
  
• House Comprehensive TB Elimination Act seeks to empower U.S. health officials to tackle tuberculosis
  
• Though life-threatening, tuberculosis not a death sentence – Expert
  
• Talk to focus on subpar treatment of Native women with tuberculosis
  
• Impact Of Covid-19 Pandemic Extends To Tuberculosis And Neglected Tropical Diseases
  
• The COVID pandemic must lead to tuberculosis vaccines
  
• Sen. Menendez, TB aid is desperately needed in the time of COVID-19 | Opinion
  
• Call for action on TB as deaths rise for first time in decade
  
• COVID-19 Pandemic Threatens to Undo Years of Progress in Tuberculosis Control
  
• ​Global tuberculosis progress reversed by COVID-19 pandemic
  
• How COVID-19 threatens to undo years of progress in TB control
  
• Will New Scientific Breakthroughs Spur The #endTB Efforts?
  
• COVID-19 and tuberculosis co-infection in pregnancy - A case series and review
  
• This Partnership Is Saving Millions of Lives Through Tackling AIDS, TB, Malaria & COVID-19. But How?
  
• Household Transmission of SARS-CoV-2 from Children and Adolescents
  
• The COVID pandemic must lead to tuberculosis vaccines
  
• VIETNAM LEADS THE WAY WITH SOS STOOL METHOD TO DIAGNOSE TB
  
• Study identifies need to improve patient retention in the National TB Elimination Programme, highlights patients’ trust relationship with private providers
  
• Biomarker for Individualized Therapy Durations in Patients With TB
  
• Promising new JCU tuberculosis research funded
  
• Regular TB screening cost-effective way to prevent spread in vulnerable areas: study
  
• Regular screening for tuberculosis in Inuit communities is cost-effective
  
• Regular TB screening cost-effective way to prevent spread in vulnerable areas: study
  
• Tuberculosis Case Reported at Metropolitan Correctional Center San Diego
  
• US-CDC supports Rivers with integrated HIV, TB, COVID-19 screening   
  
• UTEP Researcher awarded $1.5M NIH Grant; Money will help in battle against Tuberculosis   
  
• Statement from TAG’s TB Project on Today’s WHO Global TB Report
  
• This Partnership Is Saving Millions of Lives Through Tackling AIDS, TB, Malaria & COVID-19. But How?
  
• Opinion: WHO numbers underscore urgent need for stronger leadership and ambitious TB recovery plan
  
• Opinion: Quality Tuberculosis care starts with people
  
• EndTB clinical trial for multidrug-resistant TB completes enrolment
  
• Fingerstick blood test can be a promising TB screening tool, study finds
  
• Largest ever global study of tuberculosis identifies genetic causes of drug resistance
• Simple Breathing Can Transmit TB More Effectively than Cough – New Research Debunks Old Convictions About Transmission   
  
• Double Trouble: The Surprising Connection Between Diabetes and Tuberculosis
  
• New data support shorter regimen for resistant TB
  
• OPINION | Quality Tuberculosis care starts with people
  
• Panganai’s Story of #TBCourage
  
• ‘A global wake-up call’: In shadow of COVID-19, TB deaths rise for first time in 15 years
  
• Global TB deaths are rising — and COVID gets the blame
  
• TB progress ‘unravelling’ due to COVID-19, WHO warns
  
• The Fight Against Drug-Resistant Tuberculosis
  
• The COVID pandemic must lead to tuberculosis vaccines
  
• New hope for patients as ‘gruelling’ treatment for drug resistant TB could be cut to six months
  
• Travel history and challenges of screening for latent TB infection in child asylum seekers
  
• Risk of childhood TB from non-adherence to isoniazid chemoprophylaxis
  
• Clinical profile and outcomes of paediatric central nervous system tuberculomas
  
• Building support systems to tackle tuberculosis for the most vulnerable
  
• New shorter treatment regimen found to be safer, more effective at treating drug-resistant TB   
  
• WHO numbers underscore urgent need for stronger leadership and ambitious TB recovery plan   
  
• FiberCel Spine Surgery Bone Putty Recalled for Tuberculosis Contamination   
  
• WHO: Global Tuberculosis Symposium
  
• What is tuberculosis and why are deaths rising?
  
• “Our patients deserve better”: Improving treatment for drug-resistant tuberculosis
  
• TB PRACTECAL: MSF clinical trial finds short, effective and safe drug-resistant tuberculosis treatment
  
• Largest ever global study of tuberculosis identifies genetic causes of drug resistance
  
• Coughing may not be the primary driver of TB transmission: new study
  
• STriTuVaD Clinical Trial of RUTI® vaccine for Tuberculosis: First Patient recruited at AIIMS, India
  
• Tuberculosis, Like Covid, Spreads by Breathing, Scientists Report
  
• Opinion: Tuberculosis deaths are rising again — and covid is to blame
  
• Why Public Health Faces a Crisis Across the U.S.
  
• Deaths from tuberculosis rose in 2020, for the first time in a decade, the W.H.O. says.
  
• Launch of the IJTLD Clinical Standards for Lung Health
  
• Tuberculosis case confirmed in Concord School District
  
• Pandemic Disruptions Blamed for First Increase in Estimated Tuberculosis Deaths in More Than a Decade
  
• Notes from the Director
  
• Statement from TAG’s TB Project on Today’s WHO Global TB Report
  
• Russell lab wins grant to develop new tuberculosis drugs
  
• TB Alliance Expands Board of Directors
  
• Remembering Herndon's History: TB And A Letter To Charles Burton
  
• Characteristics of genitourinary tuberculosis in Sri Lanka: A retrospective cohort study
  
• BCG: the history and modern-day uses of the tuberculosis vaccine
  
• Technical Advisory Group on Tuberculosis Diagnostics and Laboratory Strengthening
  
• Key Highlights: Official UN General Assembly Side Event: Progress and Multisectoral Action Towards Achieving Global Targets to End TB
  
• TB civil society, parliamentarians, and TB survivors call for accountability and community led monitoring to ensure access to TB treatment and care for all
  
• International Support for Compulsory License to Address Access Barriers to Life-saving Tuberculosis Medicines, Bedaquiline and Delamanid
  
• Postoperative Complications of Surgery for Tuberculosis Destroyed Lung
  
• COVID pandemic demonstrates why U.S. should fund more tuberculosis prevention work
  
• Co-Infection with 4 Species of Mycobacteria Identified by Using Next-Generation Sequencing
  
• Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020
  
• Tuberculosis outbreaks declared in northern First Nations communities
  
• DOST study to halt drug-resistant TB reports 70% to 80% success rate  
• Diabetes-associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia
  
• ​COVID-19 Measures Are Soft Compared With Tuberculosis Rules
  
• Chief Medical Officer Was Silenced in Canada's Residential Schools
  
• Identification of novel chemical scaffolds that inhibit the growth of Mycobacterium tuberculosis in macrophages
  
• Tuberculosis Elimination Loses to COVID-19 Pandemic​
  
• 2021 may be worse for tuberculosis
  
• COVID-19 combined with funding shortfalls are devastating efforts to end Tuberculosis (TB) by 2030- New data shows
  
• Biochemists detail protein vital to tuberculosis, antibiotic resistance
  
• Report: COVID-19, lack of funding are hampering TB response
  
• Audit hits Donovan state prison for shoddy tuberculosis care, loose injectable handling
  
• UN has pledged support to end tuberculosis in Nigeria-Kalu, Reps Spokesman
  
• World-first study links long-term disabilities and TB
  
• The Pandemic Has Set Back the Fight Against H.I.V., TB and Malaria
  
• Global Progress Against HIV, TB, Malaria Faltered During Pandemic
  
• COVID-19 disruption causing many deaths from TB, AIDS in poorest countries, fund says
  
• ​COVID-19 Causes Major Interruption in Global HIV Progress
  
• Pandemic reverses TB testing gains, Bicol‌ and ‌Apayao‌ ‌are exceptions  
  
• Her husband died in a tuberculosis outbreak. She wants more testing on human tissue products.
  
• TB Alliance, Lupin partner for new anti-tuberculosis drug
  
• How Manila is using its COVID-19 response to find TB patients
  
• Severe COVID can awaken ‘dormant TB,’ says doctor and tuberculosis researcher
  
• Only 2% TB patients infected with Covid
  
• MSF: Lifesaving TB (Tubercolosis) Medicines Still Out Of Reach For Children In High-Burden Countries
  
• Countryside continues to monitor TB cases in its five counties
  
• Medical alliance works to bring down cost of TB tests
  
• Fighting tuberculosis with medication, mental health and social support
  
• Luwero sees increase in TB treatment success rate
  
• Vitamin D deficiency does not increase TB risk in young children
  
• Study: Long-term disabilities linked to TB
  
• Tuberculosis Diagnosed In 151 Covid-Recovered Individuals In Karnataka
  
• Pandemic reverses TB testing gains, Bicol‌ and ‌Apayao‌ ‌are exceptions  
  
• International Day for the Eradication of Poverty: the role of clinical studies in testing interventions
  
• Renovation of former tuberculosis facility unearths 130 years of Colorado history
  
• Respiratory syncytial virus, tuberculosis, liver abscess infections surge as post-COVID symptoms among children
  
• COVID-19 Has Devastated HIV and TB Services According to New Global Fund Report
  
• TB Alliance and Lupin announce commercial partnership for new therapy for highly drug-resistant TB
  
• WHO framework strengthens accountability across sectors for ending TB by 2030
  
• Mozambique: Over 3,000 Patients Under New TB Combined Therapy
  
• Covid Coughs Up New Problem: A Greater Vulnerability To TB
  
• SHAH: Pandemic policies are not new
  
• Comparison of 3 Preventive Tuberculosis Therapies in Patients With HIV Infection
  
• TB incidence in US higher among older adults but declining rapidly within birth cohorts
  

Suscribe to the TB WIRE today!

​​​Market Analyses:​

• Tuberculosis Diagnosis and Treatment Market Size, Key Company Profiles, Types, Applications and Forecast To 2027
  
• Tuberculosis Testing Market Report 2021 Market SWOT Analysis,Key Indicators,Forecast 2027 : Abbott Laboratories, Akonni Biosystems, Alere
  
• Tuberculosis Testing Technology Market to Witness Huge Growth by 2028 | Thermo Fisher Scientific, Alere, Epistem
  
• Global Anti-Tuberculosis Therapeutics Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals PLC, Lannett, Mylan N.V., Teva Pharmaceutical Industries Ltd
  
• Tuberculosis Drugs Market Trends, Top Manufactures, Tuberculosis Drugs Market Demands, Industry Growth Analysis & Forecast 2026
  
• BCG Vaccine Market By Type (Immune BCG, Therapy BCG), Application Type (Hospitals, Clinics, Others), And Region- Global Forecast To 2028
  
• Global BCG Tuberculosis (TB) Vaccine Market: How Much Will Be the Total Production in 2027? with Top Companies Like:Sanofi Pasteur, Japan BCG Lab, China National Biotec
  
• Tuberculosis Testing Market Innovative Strategy by 2028 | Abbott Laboratories, Akonni Biosystems, Abbott
  
• Tuberculosis Drugs Market CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast to 2028 | ohnson & Johnson Services, LLC, Lupin Ltd, Novartis AG
  
• Tuberculosis Drugs Competitor Analysis Report - Global Forecast to 2026
• Tuberculosis Diagnostics Competitor Analysis Report - Global Forecast to 2026
  
• Tuberculosis Testing Competitor Analysis Report - Global Forecast to 2026
  
• Tuberculosis Testing Market Industry Analysis, Geographical Segmentation, Drivers, Challenges, Trends Forecasts Report 2021 -2026 – Hoffmann-La Roche AG, Hain LifeScience GmbH, Hologic Corporation, etc.
  
• Tuberculosis Prevention and Treatment Vaccine Market Size 2021 Growing Rapidly with Upcoming Trends, New Development Strategy, Competitive Landscape and Growth by Forecast 2027
  
• Tuberculosis Vaccines Market Professional Survey 2021 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026
  
• Tuberculosis Vaccine Treatment Market  Insights, Status, Latest Amendments and Outlook 2021 – 2027 |Top key players: Merck & Co., Inc.(US), Sanofi Pasteur SA (France)
  
• Tuberculosis Vaccine Treatment Market SWOT Analysis,Key Indicators,Forecast 2027 : Merck,Japan BCG Lab,Serum Institute of India,AJ Vaccines
  
• Tuberculosis Vaccine Treatment Market Growth Factor Details for Business Development Forecasts 2027 – Serum Institute of India, AJ Vaccines
  
• Tuberculosis Treatment Market 2021-2027 Global Industry Outlook- Sanofi, Bayer, Eli Lilly, Labatec Pharma, Novatis
  
• Tuberculosis Treatment Drugs Market 2021 | Scope of Current and Future Industry 2027
  
• Tuberculosis Testing Market Drivers And Restraints For Each Segment
  
• Tuberculosis Drugs Market Ultimate Analysis by Source, Sales Channel, Formulation & Global Forecast to 2027
  
• Tuberculosis Drugs Market Size 2021 Key Strategies, Applications, Trends and Opportunities
  
• Tuberculosis Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
  
• Tuberculosis (TB) Treatment Market Size, Latest Trends, Growth and Share 2021 | Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Macleods Pharmaceutical Ltd
• Mycobacterium Tuberculosis Market Future Outlook of Statistics on Industry Growth till 2026| Thermo Fisher Scientific, Danaher, Mediven, Osang Healthcare, Hologic
  
• GLOBAL TUBERCULOSIS VACCINE TREATMENT MARKET REPORT FUTURE PROSPECTS, GROWTH, OUTLOOK AND FORECAST 2021-2026
  
• Global Tuberculosis Therapeutics Market Statistics, Development and Growth Market Players 2022-2027
  
• Global Tuberculosis Drugs Market Development Prospects 2021-2027 | By Pfizer Inc, Cipla Ltd, AstraZeneca Plc, Novartis AG
  
• Tuberculosis Diagnosis and Treatment Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027
  
• Infectious Disease Molecular Diagnostics Market Size Worth $40.8 Billion By 2028: Grand View Research, Inc. 
  
• Tuberculosis Testing Technology Market (2021-2027) Demand Analysis, Global Business Growth | F. Hoffmann-La Roche AG, QIAGEN, Cepheid Inc., Hologic, Sanofi S.A., Abbott Laboratories, BioMérieux, Thermo Fisher Scientific, etc 
  
• TB Vaccines Market Major Geographies, Prominent Players Review and Forecast 2021 to 2027
  
• Tuberculosis Treatment Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth
  
• TUBERCULOSIS VACCINE TREATMENT MARKET ANALYSIS BY SIZE, SHARE, GROWTH, APPLICATION, SEGMENTATION AND FORECAST TO 2026
  
• LATENT TUBERCULOSIS TESTING MARKET SHARE TO RECORD ROBUST GROWTH THROUGH 2026
  
• Tuberculosis Testing Market Size,Forecast,and Top Firms : Abbott Laboratories,Akonni Biosystems,Alere,,Becton,Dickinson and Company,Cepheid​
  
• Global Tuberculosis (TB) Detection Market Growing Popularity and Emerging Trends 2021-2028 Danaher, Hain Lifescience, Abbott
• Global Tuberculosis (TB) Detection Market Growing Popularity and Emerging Trends 2021-2028 Danaher, Hain Lifescience, Abbott
  
• Tuberculosis Treatment Market Size, Share, Future Opportunities 2028 | Sanofi, Otsuka, Labatec Pharma, Bayer, Novatis, Eli Lilly, Pfizer, etc.
  
• Qualitative analysis of Tuberculosis Testing and Diagnostics Market Revenue & Industry Analysis By 2026
  
• Tuberculosis Testing Market research and analysis by expert top companies, growth drivers, industry challenges, and opportunities to 2028
  
• Global Anti-Tuberculosis Therapeutics Market Forecast to 2027 Size, Share, Upcoming Trends Segmentation, Top Players like Lupin, Johnson and Johnson Services Inc, Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals
  
• Global BCG Tuberculosis Vaccine Market Report Forecast to 2021-27- GREENSIGNAL BIO PHARMA LIMITED, INTERVAX LTD, JAPAN BCG LABORATORY
  
• Tuberculosis Drugs Market to Eyewitness Massive Growth by EIKEN CHEMICAL, Sandoz, Archivel Farma
  

​

Reports​

• GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis
  
• Global Fund Board Approves New Strategy Placing People and Communities at Center to Lead Fight Against HIV, TB, Malaria, to Build Systems for Health, Equity and Strengthen Pandemic Preparedness
  
• ACTG announces launch of clinical trial evaluating a three-month TB treatment
  
• Fighting Pandemics and Building a Healthier and More Equitable World - Global Fund Strategy (2023-2028)
  
• Global Pulmonary Tuberculosis Clinical Trials Report H2, 2021: Phase, Trial Status, End Points Status and Sponsor Type Review - ResearchAndMarkets.com
  
• ACTG Announces Initiation Of CLO-FAST, Its First Trial Evaluating A Three-Month TB Treatment
  
• Research in Action Awards 2021
  
• The Challenge of Diagnosing HIV Infection in LA PrEP Users
  
• PrEPared? Long-Acting PrEP Access in Communities Marginalized by the U.S. Healthcare System
  
• The Lancet Commission on diagnostics: transforming access to diagnostics
  
• Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies
  
• Long-Acting Therapy for Malaria Prevention: Toward a Malaria-Free World
  
• USAID'S COVID-19 RESPONSE: LATEST NEWS
  
• Terraforming the Policy Landscape to Enable Access to Long-Acting Technologies
  
• Know Your CAB: Community Experts Shaping the Long-Acting Technologies Pipeline
  
• Delivering on the Promise of Long-Acting Technologies
  
• Developing Long-Acting Cures to Accelerate the End of Hepatitis C: Interview with Dr. Dave Thomas
  
• Injectables Redux: Developing Acceptable Long-Acting Formulations for TB Prevention Amidst a Push for All-Oral Treatment
  
• TAG 2021 Pipeline Report Tuberculosis Vaccines
• TAG 2021 Pipeline Report Tuberculosis Preventative Treatment 
• The International Journal of Tuberculosis and Lung Disease
  
• Mapping the Technology Landscape of National TB Programs: Report
  
• Global Lung Health Meet Opens With Top Three Science Announcements
  
• New NACCHO Case Study Series Highlights LHD and Health Center Partnerships to Address TB and COVID-19
  
• WHO Global TB Report Release
  
• People living with HIV who started tuberculosis preventive treatment
  
• Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
  
• The Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, tuberculosis, and hepatitis C
  
• Statement on the anniversary of the UN High-Level Meeting on TB
  
• ​Our Footprint at the 52nd Union World Conference on Lung Health
  
• How Can TB Services for Adolescents and Youth be Improved?
  
• A Critical Chance to End Pediatric TB in the Era of COVID-19
  
• TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference
  
• Rifampicin-Resistant Tuberculosis (RR-TB), MSF Clinical Trials Present Short And Effective Treatment
  
• WHO Global Tuberculosis Report—New Drugs and Regimens Need to be Combined with Equitable and Universal Access
  
• Press Statement: Calls for Urgent Action to Address TB Prevention Deficits Among Children and Household Contacts of People Affected by TB
  
• Anti-tuberculosis Therapeutics Market: Worldwide Analysis and Forecasts, 2021 to 2024
  
• Organic Dispersion To Drive The Drug Resistant Tuberculosis Treatment Market
  
• Reported Tuberculosis in the United States, 2020
  
• Program Evaluation: Developing and Implementing a Remediation Plan1
  
• CDC: TB Notes 3, 2021 - Notes from the Director
  
• ​Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021
  
• Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials
  
• Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis
  
• TB Alliance Expands Board of Directors
  
• Public Health Action - September 2021
  
• The Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, tuberculosis, and hepatitis C
  
• Statement on the anniversary of the UN High-Level Meeting on TB
  
• New Report: The Global Impact of Respiratory Disease - 3rd Edition
• TB Elimination Alliance Impact Report 2020-2021
  
• BMJ Awards 2021: Respiratory team of the year​
• Tuberculosis - Annual Epidemiological Report for 2019
  
• Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis
• Results Report 2021
  
• Policy Research Report - From Siloes to Synergies: Integrating noncommunicable disease prevention and care into global health initiatives and universal health coverage 
  
• Bovine TB: epidemiology reports, 2020
  
• Assembly Side Event: Progress and Multisectoral Action Towards Achieving Global Targets to End TB
  
• ​A second call for case studies of programmatic innovations to address challenges in TB prevention and care during the COVID-19 pandemic
  

​